Medicure Inc (MCUJF) 4.6360 $MCUJF
Medicure Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 11, 4:00PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended March 31, 2016.
MPH.VN: 5.950 (+0.100)
Medicure Files Application for New AGGRASTAT® Product Format
CNW Group - Wed May 11, 7:00AM CDT
Expects to Launch Bolus Vial in Q3 2016
MPH.VN: 5.950 (+0.100)
Medicure Announces Departure of President and Chief Operating Officer
PR Newswire - Mon May 09, 6:00PM CDT
Medicure Inc. ("Medicure" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company today announced that the employment agreement with President and Chief Operating Officer, Dawson Reimer, has been terminated, effective immediately. "I and the entire Board of Directors thank Dawson for his commitment and dedication throughout his years of service with Medicure. We wish him all the best in his new endeavours," said Dr. Albert Friesen, Board Chair and CEO of Medicure Inc.
MPH.VN: 5.950 (+0.100)
Medicure to Announce Q1 2016 Financial Results on May 11, 2016
PR Newswire - Wed May 04, 6:00PM CDT
Medicure Inc. ("Medicure" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will release financial results for the first quarter ended March 31, 2016 after market close on Wednesday, May 11, 2016. Medicure will hold a conference call and webcast regarding the results on Thursday, May 12 2016, at 7:30 AM Central Time (8:30 AM Eastern Time).
MPH.VN: 5.950 (+0.100)
Medicure Announces Grant of Options
CNW Group - Thu Apr 07, 3:25PM CDT
Medicure Inc. (the "Company" (TSXV:MPH, OTCQB:MCUJF) announces today that its Board of Directors has approved the grant of an aggregate of 265,025 options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to the Company's Stock Option Plan. Of these options, 225,025 are set to expire on the fifth anniversary of the date of grant and 40,000 are set to expire on the first anniversary of the date of grant. All of the options were issued at an exercise price of $6.16 per share. The options are subject to the approval of the TSX Venture Exchange.
MPH.VN: 5.950 (+0.100)
Medicure Announces Upcoming Conference Presentations
CNW Group - Tue Apr 05, 8:00AM CDT
Medicure Inc. ("Medicure" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will be participating and presenting at the following investor conferences in April and May, 2016;
MPH.VN: 5.950 (+0.100)
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2015
PR Newswire - Wed Mar 30, 4:00PM CDT
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the year ended December 31, 2015.
MPH.VN: 5.950 (+0.100)
Medicure To Announce Fiscal Year 2015 Financial Results on March 30, 2016
CNW Group - Wed Mar 23, 4:00PM CDT
Medicure Inc. ("Medicure" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will release financial results for the fourth quarter and fiscal year ended December 31, 2015 after market close on Wednesday, March 30, 2016. Medicure will hold a conference call and webcast regarding the results on Thursday, March 31 2016, at 7:30 AM Central Time (8:30 AM Eastern Time).
MPH.VN: 5.950 (+0.100)
Medicure to present at Cantech Investment Conference
PR Newswire - Thu Jan 21, 10:44AM CST
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that it will present at the 2016 Cantech Investment Conference on January 26th in Toronto.
MPH.VN: 5.950 (+0.100)
Medicure Announces Preliminary Revenue For Fiscal 2015
PR Newswire - Mon Jan 11, 8:30AM CST
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today reported unaudited net revenue for the 2015 fourth quarter and full fiscal year. All amounts referenced herein are in Canadian dollars.
MPH.VN: 5.950 (+0.100)
Medicure announces ANDA collaboration with Apicore
PR Newswire - Wed Jan 06, 7:00AM CST
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, is pleased to announce that the Company has initiated the development of a high-value cardiovascular generic drug. The project is a collaboration between Medicure International, Inc. (a wholly owned subsidiary of Medicure Inc.) and Apicore US LLC (together with its affiliates "Apicore", a leading-edge manufacturer of generic active pharmaceutical ingredients ("API's".
MPH.VN: 5.950 (+0.100)
Medicure Announces PDUFA Action Date for New Aggrastat Indication
PR Newswire - Wed Dec 02, 9:48AM CST
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA" has assigned a Prescription Drug User Fee Act ("PDUFA" action date of July 10, 2016, for completing its review of the AGGRASTAT (tirofiban HCl) supplemental New Drug Application ("sNDA" submitted by the Company. The filing of the sNDA was previously announced on September 10, 2015. If approved, the indication statement for AGGRASTAT would be expanded to include the treatment of patients presenting with ST segment elevation myocardial infarction (STEMI) intended for percutaneous coronary intervention (PCI).
MPH.VN: 5.950 (+0.100)
Medicure Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 11, 4:00PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended March 31, 2016. MPH.VN: 5.950 (+0.100)
Medicure Files Application for New AGGRASTAT® Product Format
CNW Group - Wed May 11, 7:00AM CDT
Expects to Launch Bolus Vial in Q3 2016
MPH.VN: 5.950 (+0.100)
Medicure Announces Departure of President and Chief Operating Officer
PR Newswire - Mon May 09, 6:00PM CDT
Medicure Inc. ("Medicure"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company today announced that the employment agreement with President and Chief Operating Officer, Dawson Reimer, has been terminated, effective immediately. "I and the entire Board of Directors thank Dawson for his commitment and dedication throughout his years of service with Medicure. We wish him all the best in his new endeavours," said Dr. Albert Friesen, Board Chair and CEO of Medicure Inc. MPH.VN: 5.950 (+0.100)
Medicure to Announce Q1 2016 Financial Results on May 11, 2016
PR Newswire - Wed May 04, 6:00PM CDT
Medicure Inc. ("Medicure"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will release financial results for the first quarter ended March 31, 2016 after market close on Wednesday, May 11, 2016. Medicure will hold a conference call and webcast regarding the results on Thursday, May 12 2016, at 7:30 AM Central Time (8:30 AM Eastern Time). MPH.VN: 5.950 (+0.100)
Medicure Announces Grant of Options
CNW Group - Thu Apr 07, 3:25PM CDT
Medicure Inc. (the "Company"
(TSXV:MPH, OTCQB:MCUJF) announces today that its Board of Directors has approved the grant of an aggregate of 265,025 options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to the Company's Stock Option Plan. Of these options, 225,025 are set to expire on the fifth anniversary of the date of grant and 40,000 are set to expire on the first anniversary of the date of grant. All of the options were issued at an exercise price of $6.16 per share. The options are subject to the approval of the TSX Venture Exchange. MPH.VN: 5.950 (+0.100)
Medicure Announces Upcoming Conference Presentations
CNW Group - Tue Apr 05, 8:00AM CDT
Medicure Inc. ("Medicure"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will be participating and presenting at the following investor conferences in April and May, 2016; MPH.VN: 5.950 (+0.100)
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2015
PR Newswire - Wed Mar 30, 4:00PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the year ended December 31, 2015. MPH.VN: 5.950 (+0.100)
Medicure To Announce Fiscal Year 2015 Financial Results on March 30, 2016
CNW Group - Wed Mar 23, 4:00PM CDT
Medicure Inc. ("Medicure"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will release financial results for the fourth quarter and fiscal year ended December 31, 2015 after market close on Wednesday, March 30, 2016. Medicure will hold a conference call and webcast regarding the results on Thursday, March 31 2016, at 7:30 AM Central Time (8:30 AM Eastern Time). MPH.VN: 5.950 (+0.100)
Medicure to present at Cantech Investment Conference
PR Newswire - Thu Jan 21, 10:44AM CST
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that it will present at the 2016 Cantech Investment Conference on January 26th in Toronto. MPH.VN: 5.950 (+0.100)
Medicure Announces Preliminary Revenue For Fiscal 2015
PR Newswire - Mon Jan 11, 8:30AM CST
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today reported unaudited net revenue for the 2015 fourth quarter and full fiscal year. All amounts referenced herein are in Canadian dollars. MPH.VN: 5.950 (+0.100)
Medicure announces ANDA collaboration with Apicore
PR Newswire - Wed Jan 06, 7:00AM CST
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, is pleased to announce that the Company has initiated the development of a high-value cardiovascular generic drug. The project is a collaboration between Medicure International, Inc. (a wholly owned subsidiary of Medicure Inc.) and Apicore US LLC (together with its affiliates "Apicore", a leading-edge manufacturer of generic active pharmaceutical ingredients ("API's". MPH.VN: 5.950 (+0.100)
Medicure Announces PDUFA Action Date for New Aggrastat Indication
PR Newswire - Wed Dec 02, 9:48AM CST
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA" has assigned a Prescription Drug User Fee Act ("PDUFA" action date of July 10, 2016, for completing its review of the AGGRASTAT (tirofiban HCl) supplemental New Drug Application ("sNDA" submitted by the Company. The filing of the sNDA was previously announced on September 10, 2015. If approved, the indication statement for AGGRASTAT would be expanded to include the treatment of patients presenting with ST segment elevation myocardial infarction (STEMI) intended for percutaneous coronary intervention (PCI). MPH.VN: 5.950 (+0.100)
